
==== Front
Cardiovasc Diabetol
Cardiovasc Diabetol
Cardiovascular Diabetology
1475-2840
BioMed Central London

39227933
2424
10.1186/s12933-024-02424-7
Research
Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Wang Chung-An 1
Lin Li-Chun 2
Chen Jui-Yi 34
Wang Wei-Jie 56
Wu Vin-Cent q91421028@ntu.edu.tw

789
1 https://ror.org/05031qk94 grid.412896.0 0000 0000 9337 0481 College of Medicine, Taipei Medical University, Taipei, Taiwan
2 https://ror.org/03nteze27 grid.412094.a 0000 0004 0572 7815 Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100 Taiwan
3 https://ror.org/02y2htg06 grid.413876.f 0000 0004 0572 9255 Division of Nephrology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
4 https://ror.org/02834m470 grid.411315.3 0000 0004 0634 2255 Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
5 grid.416911.a 0000 0004 0639 1727 Division of Nephrology, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Healthy and Welfare, Taoyuan, Taiwan
6 https://ror.org/02w8ws377 grid.411649.f 0000 0004 0532 2121 Department of Biomedical Engineering, Chung Yuan Christian University, Chungli, Taiwan
7 https://ror.org/03nteze27 grid.412094.a 0000 0004 0572 7815 Primary Aldosteronism Center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
8 https://ror.org/03nteze27 grid.412094.a 0000 0004 0572 7815 National Taiwan University Hospital Study Group of Acute Renal Failure (NSARF), Consortium for Acute Kidney Injury and Renal Diseases, Taipei, Taiwan
9 https://ror.org/03nteze27 grid.412094.a 0000 0004 0572 7815 Department of Internal Medicine, National Taiwan University Hospital, Room 1555, B4, Clinical Research Building, 7 Chung-Shan South Road, Taipei, 100 Taiwan
3 9 2024
3 9 2024
2024
23 32724 6 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have demonstrated associations with lowering cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, the impact of SGLT-2is on individuals at dialysis commencement remains unclear. The aim of this real-world study is to study the association between SGLT-2is and outcomes in patients with T2DM at dialysis commencement.

Methods

This is a retrospective cohort study of electronic health records (EHRs) of patients with T2DM from TriNetX Research Network database between January 1, 2012, and January 1, 2024. New-users using intention to treatment design was employed and propensity score matching was utilized to select the cohort. Clinical outcomes included major adverse cardiac events (MACE) and all-cause mortality. Safety outcomes using ICD-10 codes, ketoacidosis, urinary tract infection (UTI) or genital infection, dehydration, bone fracture, below-knee amputation, hypoglycemia, and achieving dialysis-free status at 90 days and 90-day readmission.

Results

Of 49,762 patients with T2DM who initiated dialysis for evaluation, a mere 1.57% of patients utilized SGLT-2is within 3 months after dialysis. 771 SGLT-2i users (age 63.3 ± 12.3 years, male 65.1%) were matched with 771 non-users (age 63.1 ± 12.9 years, male 65.8%). After a median follow-up of 2.0 (IQR 0.3–3.9) years, SGLT-2i users were associated with a lower risk of MACE (adjusted Hazard Ratio [aHR] = 0.52, p value < 0.001), all-cause mortality (aHR = 0.49, p < 0.001). SGLT-2i users were more likely to become dialysis-free 90 days after the index date (aHR = 0.49, p < 0.001). No significant differences were observed in the incidence of ketoacidosis, UTI or genital infection, hypoglycemia, dehydration, bone fractures, below-knee amputations, or 90-day readmissions.

Conclusions

Our findings indicated a lower incidence of all-cause mortality and MACE after long-term follow-up, along with a higher likelihood of achieving dialysis-free status at 90 days in SGLT-2i users. Importantly, they underscored the potential cardiovascular protection and safety of SGLT-2is use in T2DM patients at the onset of dialysis.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12933-024-02424-7.

Keywords

Type 2 diabetes mellitus
Dialysis initiation
Major adverse cardiovascular events
Propensity score matching
Sodium-glucose cotransporter 2 inhibitors
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The prevalence of diabetes mellitus (DM) continues to surge on a global scale. Recent projections from the International Diabetes Federation (IDF) indicate that over half a billion individuals worldwide are currently grappling with diabetes, with expectations of a striking 46% escalation by 20451. Notably, the percentage of incident ESRD patients caused by diabetes progressively increased from 22.1% in 2000 to 31.3% in 20152. IDF also states that 30 to 40% of people living with diabetes develop CKD [3]. According to Kidney Disease Improving Global Outcomes (KDIGO), it has been estimated that 40% or more of people with diabetes will develop CKD, including a significant number who will develop kidney failure requiring dialysis or transplantation [4]. Given the well-established link between diabetes and the progression of chronic kidney disease (CKD), characterized by glomerular sclerosis, fibrosis, progressive albuminuria, and hypertension [5]. In addition to the challenges posed by diabetes-related long-term cardiovascular disease (CVD), individuals undergoing renal replacement therapy find themselves confronting an array of CVD [6, 7].

The introduction of sodium-glucose cotransporter 2 inhibitors (SGLT-2is), a novel class of oral antidiabetic drugs (OADs), has caused a paradigm shift in the treatment strategies for patients with type 2 diabetes mellitus (T2DM). These drugs have demonstrated the capacity to reduce major adverse cardiovascular events (MACE), heart failure hospitalization, and renal protection in patients with T2DM with established cardiovascular disease or those at risk [8–10]. Additionally, clinical trials have shown their benefits in patients with heart failure across the ejection fraction spectrum, regardless of the presence or absence of diabetes [11–13]. Trials specifically targeting patients with CKD have similarly shown cardio-renal protective effects. EMPA-KIDNEY trial and post-hoc analysis shows that SGLT-2is offer kidney benefits in CKD patients, irrespective of diabetes status, and even in those with estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m²14,15. The update from the Kidney Disease Improving Global Outcomes (KDIGO) guideline now recommends the initiation of SGLT-2is at a lower eGFR threshold, reducing it from 25 to 20 mL/min/1.73 m², and suggests the continuation of these medications until the need for dialysis and the UK Kidney Association Clinical Practice Guideline recommends initiation of SGLT-2is in people with an eGFR below 20 mL/min/1.73 m² to slow progression of kidney disease [4, 16]. This significant change in recommendations signifies potential advantages for individuals with diabetes who require dialysis. As of May 2023, the U.S. FDA has revised its guidance on dapagliflozin by eliminating the previous contraindication related to patients undergoing dialysis [17]. Intriguingly, a similar pattern has emerged in Europe, with the European Medical Agency (EMA) not listing dialysis as a contraindication for dapagliflozin [18]. An exploratory analysis of DAPA-CKD trial indicated no significant safety concerns in dialysis patients [19]. To address this notable gap in the literature, our study endeavors to investigate the potential association between SGLT-2is and all-cause mortality and cardiovascular outcomes in patients with T2DM who initiated dialysis, compared to those initializing dialysis but are not receiving SGLT-2is.

Methods

Data sources

In this retrospective study, we leveraged the TriNetX Research Network, a global federated health research platform, and the data in the TriNetX Research Network is sourced from healthcare organizations (HCOs) [20]. The data set encompassed a broad spectrum of information, including patient demographics, diagnoses (aligned with the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] and the International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes), procedures (documented with ICD-9-CM, the International Classification of Diseases, Tenth Revision, Procedure Coding System [ICD-10-PCS], and Current Procedural Terminology [CPT] codes), medications (coded according to the Veterans Affairs National Formulary and RxNorm ingredients), laboratory tests (categorized by LOINC), and healthcare utilization records from multiple HCOs, including hospitals, primary care units, and specialized facilities.

We utilized the TriNetX Research Network database, which includes EHRs of over 100 million patients across 93 healthcare organizations (HCOs) in five countries: Taiwan, Georgia, Colombia, Brazil, and the United States [21–27]. Patient-level data were analyzed using the built-in statistical tool on the TriNetX platform, based on Java (version 11.0.16), R (version 4.0.2, with packages Hmisc and Survival), and Python (version 3.7, with libraries lifelines, matplotlib, numpy, pandas, scipy, and statsmodels). The results were presented to investigators in an aggregated format. Further details about the database are available online and in previously published descriptions [28, 29].

This study using the TriNetX database obtained ethical approval from the Institutional Review Board of Chi-Mei Hospital, Tainan, Taiwan (No: 11202-002), and the institutional review boards of all participating hospitals. A waiver of informed consent was granted by the Western Institutional Review Board because this study was conducted using only aggregated statistical summaries of de-identified information. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki [30] and adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for its design.

Study population

In this study, a cohort was established by selecting and organizing participants from the database, covering the period from January 1, 2012, to January 1, 2024, involving 131,791,763 individuals. The study included patients aged 18 to 90 years with T2DM who initiated dialysis during this period. Patients were categorized as SGLT-2i users if they had received a prescription for an SGLT-2is within 3 months following the commencement of dialysis. Patients were categorized as SGLT-2i users if they received a prescription for an SGLT-2is within 3 months of commencing dialysis. T2DM patients who did not use SGLT-2is during the specified period were grouped as controls, in line with our intention-to-treat (ITT) design. Exclusion criteria included any instance of dialysis within 30 days before the current dialysis session, and individuals who used SGLT-2is before initial dialysis for 3 months and passed away within 3 months following their initial dialysis. These criteria aimed to identify patients with T2DM undergoing acute dialysis or newly entering chronic dialysis treatment and a new-users design also implemented to ensure SGLT-2is who did not have a prior history of using SGLT-2is. The index date was set at 90 days after dialysis commencement. To address potential sources of protopathic or ascertainment bias [31], any occurrences of outcomes that transpired before the index date were meticulously excluded from the analysis. Enrollment algorithm of participants was illustrated in Fig. 1.

Fig. 1 Enrollment algorithm for patients. BMI body mass index, T2DM type 2 diabetes mellitus, PSM propensity score matching, SBP systolic blood pressure, SGLT-2is sodium–glucose cotransporter 2 inhibitors

Outcomes

The primary outcomes centered on two critical aspects of patient health: all-cause mortality and the occurrence of major adverse cardiovascular events (MACEs) during the follow-up period. These MACEs, representing a composite outcome, encompassed non-fatal myocardial infarction, non-fatal ischemic stroke, cardiovascular death/mortality, and hospitalization for unstable angina. Secondary outcomes included 3-Point Major Adverse Cardiovascular Events (3p-MACEs), which comprised non-fatal myocardial infarction, non-fatal ischemic stroke, and cardiovascular death/mortality. Additionally, the analysis extended to other safety outcomes and side effects such as ketoacidosis, UTI or genital infection, dehydration, bone fracture, below-knee amputation, hypoglycemia, dialysis-free status at 90 days, and 90-day readmission. Patients were followed until death, the last recorded entry in their health record, the completion of 5 years of follow-up, which starting after the index date, or until July 23, 2024, whichever occurred first. The detailed diagnostic, visit, and procedural codes used to define the outcomes can be found in the Supplementary Methods. To mitigate the potential impact of protopathic or ascertainment biases, we meticulously excluded any occurrences of secondary outcomes before the index date [22].

Covariates

To account for differences in baseline characteristics between the two study groups, we incorporated specific covariate factors and potential confounding factors into our analysis. These factors included demographic variables such as age, gender, ethnicity, and race. Additionally, our analysis encompassed the evaluation of various comorbidities, including ever hospitalization within the past year, hypertensive diseases, peripheral vascular diseases, ischemic heart diseases, cerebrovascular diseases, chronic obstructive pulmonary diseases, asthma, chronic kidney disease (CKD), peritoneal dialysis, dementia, sleep disorders, depression, and neoplasms. We also considered clinical measures including body mass index (BMI), and systolic blood pressure and laboratory results such as, hemoglobin A1c, estimated glomerular filtration rate (eGFR), total cholesterol, alanine aminotransferase (ALT), B-type natriuretic peptide (BNP), potassium levels, and urine protein. Daily behaviors and habits, such as smoking and alcohol consumption and medication history were included, covering insulin, thiazolidinediones, glucagon like peptide-1-receptor (GLP-1) analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, aspirin, clopidogrel, statins, allopurinol, febuxostat, alpha-blockers, beta-blockers, calcium channel blockers (CCB), and the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).

These variables were integrated into our analysis to adjust for any variations in the baseline characteristics of the study cohorts. To ensure the accuracy of our analysis and minimize multicollinearity, we utilized quantifiable continuous variables such as body mass index (BMI) and estimated glomerular filtration rate (eGFR), categorized appropriately, instead of relying solely on categorical variables like obesity and CKD. The detailed codes used to define the covariates can be found in the Supplementary Methods.

Subgroup and sensitivity analysis

In our study, we were conducting a comprehensive subgroup analysis to explore potential variations across different subgroups. Patients were stratified according to age (≥ 65 or < 65 years), baseline estimated glomerular filtration rate (eGFR) (≥ or < 30 mL/min/1.73 m²), urine protein/creatinine ratio (UPCR) (≥ or < 300 mg/g), body mass index (BMI) (≥ or < 30 kg/m²), and HbA1c levels (≥ or < 7%). We also assessed outcomes based on the use of beta blockers, ACEI/ARB, the enrolled period (before 2018 or after 2018), the presence of cardiovascular disease (CVD), smoking history, the various types of SGLT-2is and advanced CKD (≥ or < 15 mL/min/1.73 m²).

Positive and negative controls

To assess the reliability of our analytical approach and avoid systemic bias, we conducted negative outcome controls, including the incidence of skin cancer, herniated disc, hemorrhoids, COPD, URIs, and GERD, which based on prior knowledge or expectations [32, 33]. We selected Angiotensin II Receptor Blockers (ARB) as our positive exposure control, based on literature suggesting that ARB usage is linked to a reduced risk of all-cause mortality and MACE [34–36]. For our negative exposure control, we chose Histamine Type 2 Receptor Antagonists (H2 blockers) and antidepressants (Selective Serotonin Reuptake Inhibitors, SSRI) [37, 38].

Landmark analysis for selection period and followed-up period

To address the impact of immortal or ascertainment bias, our series of landmark analyses involved initiating the follow-up period on the 14th, 30th, or 60th days post-acute dialysis. We also performed analyses across follow-up periods of 1, 2, 3, 4, and 5 years and compared these results to the overall study period. To ensure the robustness, we evaluated various exclusion criteria, including patients who died after dialysis initiation, and applied Cox regression model with different covariates. Additionally, we assessed the impact of SGLT-2is discontinuation timing by comparing continued use versus discontinuation within 3 months after the index date.

Statistical analysis

Baseline characteristics of the SGLT-2i users and non-users groups were presented numerically as mean [SD] for continuous variables and as count and percentage for categorical variables. Categorical variables were compared using chi-squared tests, and continuous variables were compared using independent 2-sample t-tests. One-to-one PSM was performed using logistic regression and greedy nearest neighbor matching based on several factors, with a caliper of 0.1 pooled standard deviations to balance baseline characteristics between the two groups. Variables were considered adequately matched if the between-group difference was below 0.1, indicating a small difference [39]. Survival probabilities were estimated using the Kaplan-Meier method. Patients were censored on the day they received a kidney transplant or after the last recorded event if that event occurred within the time window of the study. Adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models, while relative risks (RRs), odds ratios (ORs), and risk differences were also assessed.

Additionally, E values were used to provide insights into the potential impact of unmeasured confounders on the observed associations [40]. Missing data were addressed by excluding the respective cases to ensure complete datasets and maintain result integrity. Patients lost to follow-up were also excluded to minimize bias and inaccuracies due to incomplete data.

We further conducted a Bayesian analysis to update the probability of mortality based on the treatment. The prior probability of receiving treatment was set at 50%, with subsequent calculations using Bayes’ theorem to determine the posterior probability of mortality associated with SGLT-2is, which indicated a reduced risk of mortality compared to the baseline.

All statistical analyses were conducted using the analytic tool on the TriNetX platform and R, version 4.2.2. Statistical software SAS, version 9.2 (SAS Institute Inc), and Stata/MP software, version 16 (StataCorp LLC), were also used for data analysis. Statistical significance was defined as a two-tailed p-value of less than 0.05.

Result

Study population characteristics

Of 49,762 patients with T2DM who initiated dialysis for evaluation, the study population was divided into two distinct groups: the SGLT-2i users (n = 781, 1.57%) and the non-user (n = 48,981, 98.43%), based on the utilization of SGLT-2is within the first three months after the dialysis. The median follow-up period for the entire cohort was 2.0 (IQR, 0.3–3.9) years. Before PSM, the major race was Asian in both groups. SGLT-2i users had a lower percentage of White (17.4% vs. 32.5%; SD = 0.347) and Black or African American (11.7% vs. 18.2%; SD = 0.181); however, a higher percentage of Asian (64.7% vs. 33.6%; SD = 0.642) and not Hispanic or Latino (91.9% vs. 72.2%; SD = 0.529) compared to non-users. Additionally, SGLT-2i users had a higher percentage of male patients (65.6% vs. 56.6%; SD = 0.179). SGLT-2i users had lower rates of nicotine dependence and CKD but higher rates of cardiovascular comorbidities and neoplasms. They were more frequently prescribed glucose-lowering, antiplatelet, and antihypertensive drugs. Additionally, obesity, poor sugar control, and better kidney function were observed among SGLT-2i users. After PSM, both groups were well balanced in each covariate, with all standardized differences less than 0.1 (Table 1). The number of patients excluded due to the absence of any follow-up after the index date was 10 out of 771 (1.3%) in the SGLT-2i users and 10 out of 771 (1.3%) in the non-users (detailed in Table S1). The reasons for initiating dialysis are detailed in Table S2, with the advanced CKD accounting for 23.9% and 24.3% of cases, respectively. Specifically, AKI primarily stems from heart failure (37.0%) and sepsis (23.2%).

Table 1 Baseline characteristics between patients using SGLT-2is and non-users before and after propensity score matching

	Before matching	After matching	
	SGLT-2i users
(n = 781)	Non-users
(n = 48,981)	Sth
diff	SGLT-2i users
(n = 771)	Non-users
(n = 771)	Sth
diff	
Age, mean ± SD	63.3 ± 12.3	63 ± 12.8	0.027	63.3 ± 12.3	63.1 ± 12.9	0.017	
Sex, n (%)	
 Male	512 (65.6%)	27,689 (56.6%)	0.179	502 (65.1%)	507 (65.8%)	0.014	
 Female	269 (34.4%)	21,292 (43.4%)	0.179	269 (34.9%)	264 (34.2%)	0.014	
Ethnicity, n (%)	
 Not Hispanic or Latino	718 (91.9%)	35,349 (72.2%)	0.529	708 (91.8%)	723 (93.8%)	0.075	
 Hispanic or Latino	31 (4.0%)	5,030 (10.3%)	0.245	31 (4.0%)	27 (3.5%)	0.027	
 Unknown ethnicity	32 (4.1%)	8,602 (17.6%)	0.441	32 (4.2%)	21 (2.7%)	0.078	
Race, n (%)	
 American Indian or Alaska	10 (1.3%)	183 (0.4%)	0.101	10 (1.3%)	10 (1.3%)	< 0.001	
 Asian	505 (64.7%)	16,465 (33.6%)	0.642	495 (64.2%)	495 (64.2%)	< 0.001	
 Black or African American	91 (11.7%)	8,905 (18.2%)	0.181	91 (11.8%)	83 (10.8%)	0.033	
 Native Hawaiian or other Pacific Islander	10 (1.3%)	483 (1.0%)	0.029	10 (1.3%)	10 (1.3%)	< 0.001	
 White	136 (17.4%)	15,920 (32.5%)	0.347	136 (17.6%)	146 (18.9%)	0.034	
 Unknown race	39 (5.0%)	7,208 (14.7%)	0.318	39 (5.1%)	37 (4.8%)	0.002	
Daily behaviors and habits, n (%)	
 Nicotine dependence	81 (10.3%)	6,602 (13.5%)	0.006	81 (10.5%)	80 (10.4%)	< 0.001	
 Tobacco use	10 (1.3%)	518 (1.1%)	0.022	10 (1.3%)	10 (1.3%)	< 0.001	
 Alcohol-related disorders	20 (2.6%)	861 (1.8%)	0.057	19 (2.5%)	21 (2.7%)	0.016	
Comorbidities, n (%)	
 Hypertensive diseases	563 (72.1%)	35,783 (73.1%)	0.008	560 (72.6%)	554 (71.9%)	0.017	
 Ischemic heart diseases	277 (35.5%)	13,628 (27.8%)	0.171	274 (35.5%)	268 (34.8%)	0.016	
 Peripheral vascular diseases	131 (16.8%)	7,613 (15.6%)	0.037	130 (16.9%)	119 (15.4%)	0.039	
 Cerebrovascular diseases	158 (20.2%)	6,206 (12.7%)	0.209	158 (20.5%)	163 (21.1%)	0.016	
 COPD	84 (10.8%)	3,996 (8.2%)	0.092	83 (10.8%)	77 (10.0%)	0.026	
 Asthma	40 (5.1%)	2,302 (4.7%)	0.022	40 (5.2%)	35 (4.5%)	0.030	
 Chronic kidney disease	327 (41.9%)	33,173 (67.8%)	0.531	325 (42.2%)	304 (39.4%)	0.055	
 Dementia	13 (1.7%)	1,052 (2.1%)	0.031	13 (1.7%)	12(1.6%)	0.002	
 Sleep disorders	138 (17.7%)	6,954 (14.2%)	0.099	137 (17.8%)	128 (16.6%)	0.031	
 Depressive episodes	55 (7.0%)	3,782 (7.7%)	0.024	54 (7.0%)	45 (5.8%)	0.048	
 Anxiety disorders	55 (7.0%)	3,406(7.0%)	0.005	54 (7.0%)	47 (6.1%)	0.037	
 Neoplasms	229 (29.3%)	10,617 (21.7%)	0.182	229 (29.7%)	231 (30.0%)	0.006	
Medications, n (%)	
 Sulfonylureas	135 (17.3%)	4,361 (8.9%)	0.254	134 (17.4%)	139 (17.5%)	0.007	
 DPP4i	140 (17.9%)	4,172 (8.5%)	0.285	139 (18.0%)	154 (19.9%)	0.049	
 GLP-1 analogues	46 (5.9%)	907 (1.9%)	0.216	43 (5.6%)	27 (3.5%)	0.098	
 Thiazolidinedione	60 (7.7%)	1,049 (2.1%)	0.261	57 (7.4%)	63 (8.2%)	0.030	
 Insulin	419 (53.6%)	21,168 (43.2%)	0.219	416 (54.0%)	417 (54.1%)	0.003	
 Aspirin	259 (33.2%)	12,328 (25.2%)	0.183	257 (33.3%)	247 (32.0%)	0.028	
 Clopidogrel	139 (17.8%)	4,718 (9.6%)	0.243	137 (17.8%)	135 (17.5%)	0.007	
 Statins	393 (50.3%)	18,094 (40.0%)	0.281	390 (50.6%)	391 (50.7%)	0.003	
 Allopurinol	35 (4.5%)	2,383 (4.9%)	0.016	35 (4.5%)	35 (4.5%)	< 0.001	
 Febuxostat	28 (3.6%)	676 (1.4%)	0.144	28 (3.6%)	19 (2.5%)	0.068	
 Alpha-blocker	156 (20.0%)	6,326 (13.0%)	0.196	156 (20.2%)	153 (19.8%)	0.010	
 Beta-blocker	339 (43.4%)	19,940 (40.7%)	0.062	337 (43.7%)	345 (44.7%)	0.021	
 CCB	356 (45.6%)	18,075 (36.9%)	0.185	355 (46.0%)	344 (44.6%)	0.029	
 ACEI/ARB	334 (42.7%)	13,160 (26.9%)	0.373	341 (44.2%)	349 (45.3%)	0.021	
Clinical measures	
 BMI	28.1 ± 7.13	29 ± 7.22	0.124	28.1 ± 7.11	28.1 ± 6.59	0.007	
 ≥ 30 kg/m2	247 (31.6%)	18,210 (37.2%)	0.116	244 (31.6%)	256 (33.2%)	0.034	
 25–30 kg/m2	265 (33.9%)	16,159 (33.0%)	0.018	261 (33.9%)	260 (33.8%)	0.002	
 <25 kg/m2	269 (34.4%)	14,613 (29.8%)	0.099	266 (34.5%)	254 (33.0%)	0.032	
 SBP, mm [Hg]	130 ± 22.2	135 ± 25.3	0.211	130 ± 22.2	129 ± 23.7	0.013	
Laboratory results	
 eGFR	68.8 ± 33.5	47.3 ± 40	0.585	68.8 ± 33.5	69.1 ± 36.9	0.008	
 ≥ 60 mL/min/1.73m2	271 (34.8%)	12,530 (25.6%)	0.202	269 (34.9%)	276 (35.7%)	0.018	
 45–59 mL/min/1.73m2	196 (25.1%)	7212 (14.7%)	0.260	193 (25.0%)	193 (25.0%)	< 0.001	
 30–44 mL/min/1.73m2	151 (19.4%)	6834 (14.0%)	0.145	149 (19.4%)	140 (18.1%)	0.031	
 15–29 mL/min/1.73m2	102 (13.0%)	9343 (19.4%)	0.165	101 (13.1%)	104 (13.5%)	0.011	
 < 15 mL/min/1.73 m	61 (7.8%)	13,062 (26.7%)	0.518	59 (7.7%)	59 (7.7%)	< 0.001	
 Proteinuria, mg/dL	4.41 ± 26.2	7.64 ± 43.6	0.090	4.42 ± 26.3	20.6 ± 44.9	0.016	
UPCR	
 < 30 mg/g	231 (29.6%)	24,086 (49.2%)	0.406	229 (29.7%)	225 (29.2%)	0.011	
 30–299 mg/g	223 (28.6%)	9,090 (18.6%)	0.239	221 (28.7%)	227 (29.4%)	0.017	
 ≥ 300 mg/g	327 (41.9%)	15,805 (32.3%)	0.202	321 (41.6%)	319 (41.4%)	0.005	
 Total cholesterol, mg/dL	159 ± 55.6	158 ± 49.5	0.028	160 ± 55.7	157 ± 45.7	0.046	
 HbA1c	8.01 ± 2.02	7.22 ± 1.87	0.405	8.01 ± 2.03	7.9 ± 2.1	0.049	
 ≥ 7.5%	362 (46.4%)	15,245 (31.1%)	0.317	356 (46.2%)	353 (45.8%)	0.008	
 6.5–7.5%	223 (28.6%)	15,602 (31.9%)	0.072	221 (28.6%)	233 (30.3%)	0.034	
 <6.5%	196 (25.1%)	18,135 (37.0%)	0.261	194 (25.2%)	185 (24.0%)	0.027	
 ALT, units/L	32.8 ± 45.8	35.4 ± 146	0.025	32.7 ± 45.8	38.7 ± 84.2	0.089	
 Potassium, mEq/L	4.13 ± 0.53	4.22 ± 0.62	0.163	4.13 ± 0.53	4.15 ± 0.56	0.042	
 BNP, pg/mL	1,057 ± 2,355	1,327 ± 3,727	0.086	1,060 ± 2,360	1,183 ± 3,401	0.042	
 Peritoneal dialysis, n (%)	17 (2.2%)	961 (2.0%)	0.016	17 (2.2%)	19 (2.5%)	0.017	
 Prior hospitalization, n (%)	291 (37.3%)	9,849 (20.1%)	0.172	291 (37.7%)	298 (38.7%)	0.017	
ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ALT alanine aminotransferase, BMI body mass index, BNP B-type natriuretic peptide, CCB calcium channel blocker, COPD chronic obstructive pulmonary disease, DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated Glomerular filtration rate, GLP-1 glucagon-like peptide 1, HbA1c glycated hemoglobin, SBP systolic blood pressure, SD standard deviation, Std diff Standardized difference, SGLT-2i sodium–glucose cotransporter 2 inhibitor, UPCR urine Protein and Creatinine Ratio

The impact of SGLT-2is on all-cause mortality, MACEs and other outcomes

During follow-up period, 42 (5.4%) patients in the SGLT-2i users and 127 (16.5%) patients in the non-users died, while 39 (8.6%) patients in the SGLT-2i users and 106 (22.5%) patients in the non-users experienced MACE. We found a significantly lower hazard of all-cause mortality (adjusted hazard ratio (aHR) = 0.49; 95% CI = 0.34–0.69, p < 0.001) and MACE (aHR = 0.52; 95% CI = 0.36–0.75, p < 0.001) in SGLT-2i users compared with non-users (Figs. 2 and 3, Figure S1, and Table S3). The risk difference of mortality was − 11% between SGLT-2i users and non-users (95% CI=-0.14- -0.08, p < 0.001) (Table S4-5). Analysis of the individual elements of MACE revealed that cardiovascular death/mortality contributed the most to the overall MACE outcome (aHR = 0.47; 95% CI = 0.33–0.68, p < 0.001) (Table S6). The E-value for all-cause mortality was 3.54, larger than the upper limit of the confidence interval at 2.26. For MACE, the E-value was 3.28, larger than the upper limit of the confidence interval at 2.01 (Table S3). No significant differences were observed in the outcomes of ketoacidosis, UTI or genital infection, hypoglycemia, dehydration, bone fracture, below-knee amputation, and 90-day readmission (Fig. 2 and Table S7). SGLT-2i users had a significantly higher likelihood of being free from dialysis compared to non-users in 90 days after the index date, with 95.1% of SGLT-2i users achieving dialysis-free status compared to 89.5% of non-users (aHR = 0.49; 95% CI = 0.33–0.73, p < 0.001). Additionally, only a very limited number of patients in the SGLT-2i group (less than 10) underwent kidney transplantation during the study period, while no patients in the non-SGLT-2i group received a kidney transplant (Table S8).

Fig. 2 Comparison of the pre-specified outcomes of patients treated with SGLT-2is versus those non-users after prosperity score matching. The forest plots illustrated the adjusted HRs of all-cause mortality, MACE, and other secondary outcomes for SGLT-2i users versus non-users after propensity score matching. The plots present both the adjusted HRs and their 95% confidence intervals (CIs), represented as error bars. The vertical line denotes an aHR of 1.00, with lower limits of the 95% CIs exceeding 1.00 indicating a statistically significant increased risk. aHR adjust hazard ratio, 3p-MACE 3-piont major adverse cardiac event, MACE major adverse cardiac event, PS propensity score, UTI urinary tract infection

Fig. 3 Kaplan-Meier curves of the pre-specified long-term outcome. The blue curve represents individuals who are SGLT-2i users, while the purple curve represents those who are SGLT-2i non-users. Shaded areas indicate 95% CIs. (A) All-cause mortality (log-rank P < 0. 001). (B) MACE (log-rank P < 0. 001). MACE major adverse cardiac event, SGLT-2is sodium–glucose cotransporter 2 inhibitors

Negative outcome, positive and negative exposure controls

Our study revealed that there were no significant associations between SGLT-2is use and the incidence of skin cancer, herniated disc, hemorrhoids, COPD, upper respiratory infections, and GERD. The results indicated that the use of SGLT-2is was not significantly associated with a heightened risk of any of these outcomes, which aligns with prior knowledge and expectations [32, 33] (Figure S2).

Based on literature suggesting that use of ARB is linked to a reduced risk of all-cause mortality and MACE. Our findings supported these reports, showing that ARB users had a significantly lower hazard of all-cause mortality and MACE compared to non-users. Results were consistent when H2 blockers and antidepressants (SSRIs) were introduced as negative exposure controls. (Figure S2)

Subgroup and sensitivity analysis

We conducted subgroup analyses to assess the influence of various factors on study outcomes. These analyses included baseline characteristics (eGFR, UPCR, and HbA1c levels, BMI, CVD, advanced CKD, and current use of beta blockers or ACEI/ARB), demographic factors (smoking status and age) and participants enrolled before or after 2018 (Fig. 4). These results showed that SGLT-2is were associated with reduced hazard of mortality and MACE across various subgroups. However, none of the interaction p-values were greater than 0.05, indicating that these associations were consistent across all subgroups without significant variation.

Fig. 4 Subgroup analysis. The forest plots illustrated the adjusted HRs of all-cause mortality and MACE for SGLT-2is users versus non-users across various subgroups. The plots present both the adjusted HRs and their 95% confidence intervals (CIs), represented as error bars. The vertical line denotes an aHR of 1.00, with lower limits of the 95% CIs exceeding 1.00 indicating a statistically significant increased risk. Advanced CKD defined as baseline kidney function less than eGFR 15 ml/min/1.732. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BMI body mass index, CI confidence interval, CKD chronic kidney disease, CVD cardiovascular diseases, eGFR estimated, glomerular filtration rate, HbA1c Glycated Hemoglobin, aHR adjusted hazard ratio, MACE major adverse cardiac event, SGLT-2i sodium–glucose cotransporter 2 inhibitor

For the sensitivity analysis, we examined the effects of varying follow-up durations, as well as different types of SGLT-2 inhibitors used (Table S9 and Figure S3). Landmark analysis further confirmed that setting the different timeframe of selection period within 14, 30, 60 days produced consistent results (Table S10). We also employed various Cox proportional hazards regression models with different covariates, all of which consistently aligned with our primary approach (Table S11-12). The extended analysis of SGLT-2is discontinuation timing, comparing continued use versus discontinuation within 3 months after the index date, also showed consistent outcomes (Table S13).

Discussion

Our analysis suggested that among T2DM patients at dialysis initiation, the new users of SGLT-2i could be linked with a reduction in the risk of all-cause mortality, and MACE over a median follow-up period of 2.0 years. Our study did not observe significant differences in the incidence of ketoacidosis, hypoglycemia, below-knee amputations, bone fractures, UTI or genital infection, dehydration, or 90-day readmission when compared to patients not using SGLT-2is. Notably, SGLT-2i users had a higher likelihood of achieving dialysis-free status at 90 days.

Several current studies have shown that SGLT-2is improve cardiovascular outcomes in patients with T2DM [8, 10, 41, 42]. Clinical trials have established that SGLT-2is reduce the risk of renal disease progression and death from renal causes in patients with T2DM, as well as in those with CKD, regardless of their diabetes status [14, 41, 43]. SGLT-2is improve glucose control primarily by promoting glucosuria, which leads to increased insulin sensitivity and enhanced beta-cell function [44]. Beyond glycemic control, these inhibitors exert pleiotropic effects that extend to cardiovascular benefits [44–46]. The combined effect of glucose-induced osmotic diuresis and natriuresis contributes to a decrease in cardiac preload while the reduction in arterial stiffness and systemic blood pressure aids in diminishing afterload [47]. However, the exact mechanisms underlying the persistent cardiovascular benefits of SGLT-2is in patients on dialysis or with severely impaired kidney function are multifaceted and not fully understood [48].

Potential mechanisms include the inhibition of the cardiac sodium-hydrogen exchanger, which contributes to the amelioration of cardiac hypertrophy, fibrosis, and injury [49]. This concept of SGLT-2 transporter-independent cardiac benefits is supported by a bioinformatic study that used in silico modeling of RNA sequence datasets from cardiac tissues of diabetic rats treated with empagliflozin [50]. Enhancing ketogenic nutrient deprivation signaling through the upregulation of the SIRT1/PGC-1α/FGF21 pathway leads to alleviation of oxidative stress/inflammation, augmentation of autophagic flux, and increased erythropoiesis, which may contribute to improved cardiovascular outcomes and overall cellular health [51]. SGLT-2is have demonstrated beneficial of preventing adverse cardiac remodeling. In a randomized trial, change in LV mass index was shown in people with T2DM who treated with empagliflozin [52]. Collectively, these potential mechanisms are independent of proximal tubular SGLT-2 and contribute to the improvement of cardiovascular events in patients with minimal diuresis.

Our study demonstrates that T2DM patients initiating dialysis who were treated with SGLT-2is had a higher likelihood of achieving dialysis-free status at 90 days. In the post-hoc analysis from EMPA-KIDNEY trial, 245 participants were with eGFR less than 20 mL/min/1.73 m², 27% relative risk reduction in the incidence of the progression of kidney disease was consistent with the effect size in the overall population [15]. These exploratory subgroup data support the hypothesis that SGLT-2is may exert beneficial effects in patients at advanced stages of CKD. The kidney-protective effects of SGLT-2is are believed to operate through multiple mechanisms [53]. They reduce intraglomerular pressure by restoring tubuloglomerular feedback and may also exert anti-inflammatory effects and enhance mitochondrial function, collectively contributing to reduced fibrosis and oxidative stress in the kidney [45, 54].

Safety concerns regarding the use of SGLT-2is in patients with T2DM on dialysis are important. Our study suggested that SGLT-2is were not associated with ketoacidosis, hypoglycemia, below-knee amputations, bone fractures, UTI or genital infection, or dehydration. A retrospective study on seven patients with diabetes undergoing intermittent hemodialysis (iHD) over 12 months found SGLT-2is treatment to be safe, with no reported cases of euglycemic ketoacidosis, bone fractures, or amputations [55]. Further research by Barreto et al. has provided insights into the pharmacokinetics of dapagliflozin in individuals with kidney failure undergoing hemodialysis or peritoneal dialysis [56]. The findings suggest that while dapagliflozin is not dialyzable, significant drug accumulation was not observed, and no serious adverse events were reported, though the follow-up duration was short. Specifically, the DAPA-CKD trial offered insights into the use of SGLT-2is in patients with kidney failure [43]. In an exploratory analysis of 167 participants who progressed to chronic dialysis, the rates of serious adverse events were comparable between those treated with dapagliflozin and those given a placebo. However, this analysis did not specifically address the cardiovascular benefits and kidney protection associated with SGLT-2 inhibitors [19]. Consequently, further randomized clinical trials are necessary to validate these findings and explore these potential benefits in greater depth.

The consistent results across prespecified subgroups support the strength of our findings. Our study highlights the potential association between new SGLT-2i users and cardiovascular outcomes in patients with T2DM who initiated dialysis, marking an initial step in understanding this relationship. The new-users design employed in our study ensures the data’s relevance to patients starting SGLT-2is, thereby enhancing the validity of our findings. Utilizing real-world data, as demonstrated in our research, provides unique advantages, offering a broad perspective on patient information that is crucial for informing future treatment approaches and research efforts.

Our studies did have some limitations. First, the predominance of Asian participants in our study may limit the generalizability of our findings. Second, the inherent nature of retrospective designs and the potential for misclassification bias and residual confounding cannot be completely eliminated. To evaluate the influence of potential unmeasured confounding, we conducted an E-value analysis, as well as PSM and variable models of multivariate Cox proportional analysis. The findings suggest that it is unlikely for an unmeasured confounder to exert a more significant effect on the primary outcome than the use of SGLT-2is. Third, the limited number of patients initiating dialysis who used SGLT-2is within our study cohort could affect the robustness of our results. The small sample size of our cohort inherently limits the statistical power to detect heterogeneity, increasing the risk of type 2 error. Additionally, the process of selecting an appropriate control group from a large cohort may lead to challenges in finding suitable matches. This can result in increased sample imbalance and potential bias. Fourth, the shorter follow-up period limits our ability to assess long-term outcomes and sustained effects of SGLT-2is, reflecting real-world practices where these drugs are selectively prescribed. Hazard ratios alone may not fully capture clinical significance [57], so we also present absolute risks and risk differences to provide a clearer view of the potential clinical relevance. Fifth, limitations related to the dataset include its aggregated nature, which restricts the ability to trace reasons for discontinuation of prescriptions and limits the application of advanced statistical methods. Due to the constraints of the TriNetX platform, we were unable to perform either multiple rounds of PSM or competing risk analysis to enhance model precision and minimize bias. Additionally, the dataset does not provide the precise dates of dialysis initiation and/or discontinuation, or renal transplant, thereby precluding the use of time-varying models. Sixth, our study did not specifically consider the dosage of SGLT-2is. While the effects of SGLT-2is are generally not considered dose-dependent, future research may further explore this aspect to confirm consistency across different dosages. Finally, it is important to note that our study was centered on patients with T2DM at the new onset of dialysis. Our landmark analysis ensured consistent results, mitigating the possibility of guarantee-time bias or immortal time bias [58]. As a result, our findings may not extend to patients on long-term dialysis. In light of these limitations, cautious interpretation of our findings is warranted, and further research is needed to validate and expand upon our observations.

Conclusions

Our real-world study suggested that new SGLT-2i users in T2DM patients at the onset of dialysis were associated with a reduced long-term risk of all-cause mortality and MACE over a median follow-up of 2.0 years. Additionally, they would have a higher likelihood of achieving dialysis-free status at 90 days without an increased risk of serious adverse events such as ketoacidosis, hypoglycemia, or infections. Further randomized clinical trials are essential to fully validate these findings and explore the cardiovascular and kidney protective effects in this population.

Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Electronic supplementary material

Supplementary Material 1

Supplementary Material 2

Author contributions

All author had full access to all the data in the study and takes responsibility for the integrity and accuracy of the data analysis. The research study and methodology were conceptualized by V.C.W. and C.A.W. V.C.W., L.C.L., and C.A.W. conducted the data analysis and literature search. V.C.W. and L.C.L. were responsible for visualizing and interpreting the data. C.A.W. undertook the writing of the original draft and drafting of the manuscript. V.C.W., W.J.W., and L.C.L. supervised the work and reviewed the edited manuscript. Statistical analysis was performed by V.C.W. and C.A.W. V.C.W. and J.Y.C. provided administrative, technical, or material support. All authors contributed to the discussion and interpretation of the results, critically reviewed and approved the final manuscript.

Funding

The research did not receive any specific grant from funding agencies in public, commercial, or not-for-profit sectors.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Sun H Saeedi P Karuranga S IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 Diabetes Res Clin Pract 2022 183 109119 10.1016/j.diabres.2021.109119 34879977
Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. 10.1016/j.diabres.2021.109119.34879977 10.1016/j.diabres.2021.109119
2. Cheng HT Xu X Lim PS Hung KY Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015 Diabetes Care 2021 44 1 89 97 10.2337/dc20-1913 33203706
Cheng HT, Xu X, Lim PS, Hung KY. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care. 2021;44(1):89–97. 10.2337/dc20-1913.33203706 10.2337/dc20-1913
3. Federation ID. Diabetes and kidney disease: the latest data from the IDF diabetes atlas and the iCaReMe registry. 2024. Accessed 4 Aug 2024. https://diabetesatlas.org/atlas/diabetes-and-kidney-disease/
4. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int 2024 105 4s S117 314 10.1016/j.kint.2023.10.018 38490803
KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117-314. 10.1016/j.kint.2023.10.018.38490803 10.1016/j.kint.2023.10.018
5. Yu SM Bonventre JV Acute kidney injury and progression of diabetic kidney disease Adv Chronic Kidney Dis 2018 25 2 166 80 10.1053/j.ackd.2017.12.005 29580581
Yu SM, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Adv Chronic Kidney Dis. 2018;25(2):166–80. 10.1053/j.ackd.2017.12.005.29580581 10.1053/j.ackd.2017.12.005
6. Stein G Fünfstück R Schiel R Diabetes mellitus and dialysis Minerva Urol Nefrol 2004 56 3 289 303 15467507
Stein G, Fünfstück R, Schiel R. Diabetes mellitus and dialysis. Minerva Urol Nefrol. 2004;56(3):289–303.15467507
7. Sowers JR Lester MA Diabetes and cardiovascular disease Diabetes Care 1999 22 Suppl 3 C14 20 10189558
Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care. 1999;22(Suppl 3):C14-20.10189558
8. Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 26 22 2117 28 10.1056/NEJMoa1504720
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;26(22):2117–28. 10.1056/NEJMoa1504720.10.1056/NEJMoa1504720
9. Neal B Perkovic V Mahaffey KW Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 17 7 644 57 10.1056/NEJMoa1611925
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;17(7):644–57. 10.1056/NEJMoa1611925.10.1056/NEJMoa1611925
10. Wiviott SD Raz I Bonaca MP Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 2019 24 4 347 57 10.1056/NEJMoa1812389
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;24(4):347–57. 10.1056/NEJMoa1812389.10.1056/NEJMoa1812389
11. McMurray JJV Solomon SD Inzucchi SE Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 2019 21 21 1995 2008 10.1056/NEJMoa1911303
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;21(21):1995–2008. 10.1056/NEJMoa1911303.10.1056/NEJMoa1911303
12. Packer M Anker SD Butler J Cardiovascular and renal outcomes with empagliflozin in heart failure N Engl J Med 2020 8 15 1413 24 10.1056/NEJMoa2022190
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;8(15):1413–24. 10.1056/NEJMoa2022190.10.1056/NEJMoa2022190
13. Anker SD Butler J Filippatos G Empagliflozin in Heart failure with a preserved ejection fraction N Engl J Med 2021 14 16 1451 61 10.1056/NEJMoa2107038
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;14(16):1451–61. 10.1056/NEJMoa2107038.10.1056/NEJMoa2107038
14. Herrington WG Staplin N Wanner C Empagliflozin in patients with chronic kidney disease N Engl J Med 2023 12 2 117 27 10.1056/NEJMoa2204233
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;12(2):117–27. 10.1056/NEJMoa2204233.10.1056/NEJMoa2204233
15. Roddick AJ Wonnacott A Webb D UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update BMC Nephrol 2023 25 1 310 10.1186/s12882-023-03339-3
Roddick AJ, Wonnacott A, Webb D, et al. UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 update. BMC Nephrol. 2023;25(1):310. 10.1186/s12882-023-03339-3.10.1186/s12882-023-03339-3
16. UK Kidney Association. UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. UK Kidney Association. Accessed 17 Oct 2023. https://guidelines.ukkidney.org/
17. U.S. Food and Drug Administration. FARXIGA® (dapagliflozin) tablets, for oral use. U.S. Food and Drug Administration. Updated May 2023. Accessed 17 Oct 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf
18. European Medicines Agency. Dapagliflozin Viatris: EPAR - Product Information. European Medicines Agency. Updated April 2023. Accessed 17 Oct 2023. https://www.ema.europa.eu/en/documents/product-information/dapagliflozin-viatris-epar-product-information_en.pdf
19. Heerspink HL, Wheeler DC, Jong N, #3382, Reasons for dialysis initiation and safety of dapagliflozin among dialysis participants, et al. new insights from DAPA-CKD. Nephrol Dialysis Transplantation. 2023;38(Supplement1). 10.1093/ndt/gfad063a_3382.
20. Wang W Wang CY Wang SI Wei JC Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks EClinicalMedicine 2022 53 101619 10.1016/j.eclinm.2022.101619 35971425
Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. 10.1016/j.eclinm.2022.101619.35971425 10.1016/j.eclinm.2022.101619
21. Pan H-C Chen J-Y Chen H-Y Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease JAMA Netw Open 2024 7 1 e2350050 2350050 10.1001/jamanetworkopen.2023.50050 38170522
Pan H-C, Chen J-Y, Chen H-Y, et al. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw Open. 2024;7(1):e2350050–2350050. 10.1001/jamanetworkopen.2023.50050.38170522 10.1001/jamanetworkopen.2023.50050
22. Wu VC Chen JY Lin YH Wang CY Lai CC Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism J Microbiol Immunol Infect 2023 56 6 1158 68 10.1016/j.jmii.2023.09.005 37827953
Wu VC, Chen JY, Lin YH, Wang CY, Lai CC. Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism. J Microbiol Immunol Infect. 2023;56(6):1158–68. 10.1016/j.jmii.2023.09.005.37827953 10.1016/j.jmii.2023.09.005
23. Pan HC Chen JY Chen HY GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease Nat Commun 2024 13 1 5912 10.1038/s41467-024-50199-y
Pan HC, Chen JY, Chen HY, et al. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;13(1):5912. 10.1038/s41467-024-50199-y.10.1038/s41467-024-50199-y
24. Lai HW See CY Chen JY Wu VC Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists Cardiovasc Diabetol 2024 29 1 277 10.1186/s12933-024-02364-2
Lai HW, See CY, Chen JY, Wu VC. Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2024;29(1):277. 10.1186/s12933-024-02364-2.10.1186/s12933-024-02364-2
25. Chuang MH Chen JY Wang HY Jiang ZH Wu VC Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes JAMA Netw Open 2024 1 8 e2427258 10.1001/jamanetworkopen.2024.27258
Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024;1(8):e2427258. 10.1001/jamanetworkopen.2024.27258.10.1001/jamanetworkopen.2024.27258
26. Wu VC Chen JY Lin YH Wang CY Lai CC Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism J Microbiol Immunol Infect 2023 10.1016/j.jmii.2023.09.005 38171981
Wu VC, Chen JY, Lin YH, Wang CY, Lai CC. Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism. J Microbiol Immunol Infect. 2023. 10.1016/j.jmii.2023.09.005.38171981 10.1016/j.jmii.2023.09.005
27. Topaloglu U Palchuk MB Using a federated network of real-world data to optimize clinical trials operations JCO Clin Cancer Inf 2018 2 1 10 10.1200/cci.17.00067
Topaloglu U, Palchuk MB. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inf. 2018;2:1–10. 10.1200/cci.17.00067.10.1200/cci.17.00067
28. Palchuk MB London JW Perez-Rey D A global federated real-world data and analytics platform for research JAMIA Open 2023 6 2 ooad035 10.1093/jamiaopen/ooad035 37193038
Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open Jul. 2023;6(2):ooad035. 10.1093/jamiaopen/ooad035.37193038 10.1093/jamiaopen/ooad035
29. Pan H-C Chen J-Y Chen H-Y GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease Nat Commun 2024 15 1 5912 10.1038/s41467-024-50199-y 39003287
Pan H-C, Chen J-Y, Chen H-Y, et al. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;15(1):5912. 10.1038/s41467-024-50199-y.39003287 10.1038/s41467-024-50199-y
30. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects Jama 2013 27 20 2191 4 10.1001/jama.2013.281053
World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;27(20):2191–4. 10.1001/jama.2013.281053.10.1001/jama.2013.281053
31. Pan HC Chen JY Chen HY Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease JAMA Netw Open 2024 2 1 e2350050 10.1001/jamanetworkopen.2023.50050
Pan HC, Chen JY, Chen HY, et al. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw Open. 2024;2(1):e2350050. 10.1001/jamanetworkopen.2023.50050.10.1001/jamanetworkopen.2023.50050
32. Tang H Yang K Song Y Han J Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes Diabetes Obes Metab 2018 20 12 2919 24 10.1111/dom.13474 30039616
Tang H, Yang K, Song Y, Han J. Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(12):2919–24. 10.1111/dom.13474.30039616 10.1111/dom.13474
33. Wang YW Lin JH Yang CS Meta-analysis of the association between new hypoglycemic agents and digestive diseases Med (Baltimore) 2022 26 34 e30072 10.1097/md.0000000000030072
Wang YW, Lin JH, Yang CS. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Med (Baltimore). 2022;26(34):e30072. 10.1097/md.0000000000030072.10.1097/md.0000000000030072
34. Qiao Y Shin JI Chen TK Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate JAMA Intern 2020 1 5 718 26 10.1001/jamainternmed.2020.0193
Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern. 2020;1(5):718–26. 10.1001/jamainternmed.2020.0193.10.1001/jamainternmed.2020.0193
35. Yang CW Tzeng NS Yin YJ Angiotensin receptor blockers decrease the risk of major adverse cardiovascular events in patients with end-stage renal disease on maintenance dialysis: a nationwide matched-cohort study PLoS ONE 2015 10 10 e0140633 10.1371/journal.pone.0140633 26488749
Yang CW, Tzeng NS, Yin YJ, et al. Angiotensin receptor blockers decrease the risk of major adverse cardiovascular events in patients with end-stage renal disease on maintenance dialysis: a nationwide matched-cohort study. PLoS ONE. 2015;10(10):e0140633. 10.1371/journal.pone.0140633.26488749 10.1371/journal.pone.0140633
36. Liu Y Ma X Zheng J Jia J Yan T Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials BMC Nephrol 2017 30 1 206 10.1186/s12882-017-0605-7
Liu Y, Ma X, Zheng J, Jia J, Yan T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol. 2017;30(1):206. 10.1186/s12882-017-0605-7.10.1186/s12882-017-0605-7
37. Hughes DG Dowling EA DeMeersman RE Garnett WR Karnes HT Cardiovascular effects of H2-receptor antagonists J Clin Pharmacol 1989 29 5 472 7 10.1002/j.1552-4604.1989.tb03365.x 2567740
Hughes DG, Dowling EA, DeMeersman RE, Garnett WR, Karnes HT. Cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol. 1989;29(5):472–7. 10.1002/j.1552-4604.1989.tb03365.x.2567740 10.1002/j.1552-4604.1989.tb03365.x
38. Almuwaqqat Z Jokhadar M Norby FL Association of antidepressant medication type with the incidence of cardiovascular disease in the ARIC study J Am Heart Assoc 2019 4 11 e012503 10.1161/jaha.119.012503
Almuwaqqat Z, Jokhadar M, Norby FL, et al. Association of antidepressant medication type with the incidence of cardiovascular disease in the ARIC study. J Am Heart Assoc. 2019;4(11):e012503. 10.1161/jaha.119.012503.10.1161/jaha.119.012503
39. Andrade C, Mean Difference. Standardized Mean difference (SMD), and their use in Meta-Analysis: as simple as it gets. J Clin Psychiatry Sep. 2020;22(5). 10.4088/JCP.20f13681.
40. VanderWeele TJ Ding P Sensitivity analysis in observational research: introducing the E-value Ann Intern Med 2017 15 4 268 74 10.7326/m16-2607
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;15(4):268–74. 10.7326/m16-2607.10.7326/m16-2607
41. Perkovic V Jardine MJ Neal B Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med 2019 13 24 2295 306 10.1056/NEJMoa1811744
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;13(24):2295–306. 10.1056/NEJMoa1811744.10.1056/NEJMoa1811744
42. Bhatt DL Szarek M Pitt B Sotagliflozin in patients with diabetes and chronic kidney disease N Engl J Med 2021 14 2 129 39 10.1056/NEJMoa2030186
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;14(2):129–39. 10.1056/NEJMoa2030186.10.1056/NEJMoa2030186
43. Heerspink HJL Stefánsson BV Correa-Rotter R Dapagliflozin in patients with chronic kidney disease N Engl J Med 2020 8 15 1436 46 10.1056/NEJMoa2024816
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;8(15):1436–46. 10.1056/NEJMoa2024816.10.1056/NEJMoa2024816
44. Fonseca-Correa JI Correa-Rotter R Sodium-Glucose Cotransporter 2 inhibitors mechanisms of action: a review Front Med (Lausanne) 2021 8 777861 10.3389/fmed.2021.777861 34988095
Fonseca-Correa JI, Correa-Rotter R, Sodium-Glucose. Cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021;8:777861. 10.3389/fmed.2021.777861.34988095 10.3389/fmed.2021.777861
45. Ferrannini E Muscelli E Frascerra S Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 2014 124 2 499 508 10.1172/jci72227 24463454
Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. 10.1172/jci72227.24463454 10.1172/jci72227
46. Merovci A Mari A Solis-Herrera C Dapagliflozin lowers plasma glucose concentration and improves β-cell function J Clin Endocrinol Metab 2015 100 5 1927 32 10.1210/jc.2014-3472 25710563
Merovci A, Mari A, Solis-Herrera C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015;100(5):1927–32. 10.1210/jc.2014-3472.25710563 10.1210/jc.2014-3472
47. Lytvyn Y Bjornstad P Udell JA Lovshin JA Cherney DZI Sodium glucose cotransporter-2 inhibition in Heart failure: potential mechanisms, clinical applications, and summary of clinical trials Circulation 2017 24 17 1643 58 10.1161/circulationaha.117.030012
Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in Heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;24(17):1643–58. 10.1161/circulationaha.117.030012.10.1161/circulationaha.117.030012
48. Heerspink HJL Berger S Gansevoort RT Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation Clin J Am Soc Nephrol 2023 1 11 1500 2 10.2215/cjn.0000000000000221
Heerspink HJL, Berger S, Gansevoort RT. Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation. Clin J Am Soc Nephrol. 2023;1(11):1500–2. 10.2215/cjn.0000000000000221.10.2215/cjn.0000000000000221
49. Lopaschuk GD Verma S Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review JACC Basic Transl Sci 2020 5 6 632 44 10.1016/j.jacbts.2020.02.004 32613148
Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44. 10.1016/j.jacbts.2020.02.004.32613148 10.1016/j.jacbts.2020.02.004
50. Iborra-Egea O Santiago-Vacas E Yurista SR Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes JACC Basic Transl Sci 2019 4 7 831 40 10.1016/j.jacbts.2019.07.010 31998851
Iborra-Egea O, Santiago-Vacas E, Yurista SR, et al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci. 2019;4(7):831–40. 10.1016/j.jacbts.2019.07.010.31998851 10.1016/j.jacbts.2019.07.010
51. Packer M Cardioprotective effects of Sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-Glucose cotransporter 2) inhibitors Circ Heart Fail 2020 13 9 e007197 10.1161/circheartfailure.120.007197 32894987
Packer M. Cardioprotective effects of Sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-Glucose cotransporter 2) inhibitors. Circ Heart Fail. 2020;13(9):e007197. 10.1161/circheartfailure.120.007197.32894987 10.1161/circheartfailure.120.007197
52. Verma S Mazer CD Yan AT Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial Circulation 2019 19 21 1693 702 10.1161/circulationaha.119.042375
Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;19(21):1693–702. 10.1161/circulationaha.119.042375.10.1161/circulationaha.119.042375
53. Chen JY Pan HC Shiao CC Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis Cardiovasc Diabetol 2023 27 1 290 10.1186/s12933-023-02035-8
Chen JY, Pan HC, Shiao CC, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;27(1):290. 10.1186/s12933-023-02035-8.10.1186/s12933-023-02035-8
54. Bailey CJ Day C Bellary S Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease Curr Diab Rep 2022 22 1 39 52 10.1007/s11892-021-01442-z 35113333
Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22(1):39–52. 10.1007/s11892-021-01442-z.35113333 10.1007/s11892-021-01442-z
55. De La Flor JC Villa D Cruzado L Efficacy and safety of the use of SGLT2 inhibitors in patients on incremental hemodialysis: maximizing residual renal function, is there a role for SGLT2 inhibitors? Biomedicines 2023 10.3390/biomedicines11071908 37509547
De La Flor JC, Villa D, Cruzado L, et al. Efficacy and safety of the use of SGLT2 inhibitors in patients on incremental hemodialysis: maximizing residual renal function, is there a role for SGLT2 inhibitors? Biomedicines. 2023. 10.3390/biomedicines11071908.37509547 10.3390/biomedicines11071908
56. Barreto J Borges C Rodrigues TB Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients Clin J Am Soc Nephrol 2023 1 8 1051 8 10.2215/cjn.0000000000000196
Barreto J, Borges C, Rodrigues TB, et al. Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol. 2023;1(8):1051–8. 10.2215/cjn.0000000000000196.10.2215/cjn.0000000000000196
57. Hernán MA The hazards of hazard ratios Epidemiology 2010 21 1 13 5 10.1097/EDE.0b013e3181c1ea43 20010207
Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13–5. 10.1097/EDE.0b013e3181c1ea43.20010207 10.1097/EDE.0b013e3181c1ea43
58. Buyse M Piedbois P On the relationship between response to treatment and survival time Stat Med 1996 30 24 2797 812 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V
Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med. 1996;30(24):2797–812. 10.1002/(SICI)1097-0258(19961230)15:24%3c2797::AID-SIM290>3.0.CO;2-V.10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V
